For patients on compounded GLP-1 medications from PlexusDxincluding compounded semaglutide, tirzepatide, or our Microdose GLP-1 Protocolgenetic predispositions in peptide pathways can inform symptom expectations and medication compatibility
A note on results: Real, sustainable change takes time
Enhanced Quality of Life: Achieving better weight control and blood sugar levels can lead to increased energy, improved mood, and overall enhanced well-being, contributing to a higher quality of life
The efficacy of subcutaneous semaglutide was established in the phase III SUSTAIN program (SUSTAIN 15 and 7), in which significant reductions in mean glycated hemoglobin (HbA 1c ) and body weight were demonstrated against placebo and a variety of active comparators in multiple patient groups with T2D [26,27,28,29,30,31,32,33]